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Exploring the Links Between Peptoid Antibacterial Activity and 
Toxicity
†
  
H. L. Bolt,
a
 G. A. Eggimann,
a
  C. A. B. Jahoda,
b 
R. N. Zuckermann,
c 
G. J. Sharples
*,b
, S. L. Cobb
*,a 
Peptoids are a promising class of antimicrobial agents with 
reported activities against a range of both Gram-positive and 
Gram-negative bacteria, fungi and most recently parasites. 
However, at present the available toxicity data is somewhat 
limited and as such rationally designing effective 
antimicrobial peptoids can be challenging. Herein, we present 
the toxicity profiling of a series of linear peptoids against 
mammalian cell lines (HaCaT and HepG2). The cytotoxicity of 
the peptoid library has then been correlated with their 
antibacterial properties against Gram-positive and Gram-
negative bacteria and also to the hydrophobicity of the 
peptoid sequences. The work presented provides valuable 
data to aid in the future rational design of antimicrobial 
peptoids. 
The growing prevalence of antibiotic resistance has intensified 
demand for novel antimicrobials to replace or complement 
existing treatments for infectious diseases. Recent incentives 
such as the 10 x ‘20 Initiative and the Global Antimicrobial 
Resistance Research Innovation Fund encourage investment 
and a commitment to the development of new antibacterial 
drugs.
1
 Given the effectiveness of the innate immune system 
in providing the first line of defence against infection, 
considerable research effort has focused on investigating the 
activities of antimicrobial peptides (AMPs), with a view to their 
deployment as templates for innovative therapeutic design.
2-5 
AMPs typically contain fewer than 50 amino acids, are cationic 
and play a fundamental role in host defence, functioning as 
both antimicrobial agents and modulators of the inflammatory 
response.
6-11 
AMPs display potent antimicrobial activity against 
a range of clinically important pathogens, including bacterial, 
fungal and parasitic species.
12-16
 However, despite promising 
biological properties, AMPs are highly susceptible to 
degradation by host proteinases, which has hindered their 
exploitation as novel therapeutics including limited success in 
clinical trials.
2-8,15-19
 
In the search for peptidomimetics that retain potent 
antimicrobial activity yet also exhibit enhanced proteolytic 
stability, α-peptoids (N-substituted glycines) have emerged as 
highly promising candidates. In α-peptoids, the side chain of 
each residue (monomer) is located on the nitrogen in the 
amide backbone (Figure 1). This allows peptoids to keep many 
of the advantageous properties of AMPs (e.g. amphilicity) but, 
with the inclusion of a tertiary amide backbone, significantly 
improve their resistance to enzymatic degradation.
20
 
 
 
Figure 1. Representative structures of an α-peptide and an α-peptoid. 
, Peptoids have been shown to have potency against a wide 
variety of Gram- positive and negative bacteria,
21-30
 parasites
31-
33
 and fungi.
25,34-36
 These studies highlight the clear potential 
that peptoids offer as a new class of antimicrobials but in 
order to progress their clinical development a more detailed 
study of their toxicity towards mammalian cells needs to be 
undertaken.  
Peptoid toxicity is often evaluated by haemolytic activity, 
however, these assays cannot necessarily be used to predict 
toxicity more generally against mammalian cells. For example, 
many peptoids in the literature are based upon peptoid 
(NLysNspeNspe)4 (compound 13, Table 1) which exhibits 
excellent antimicrobial properties, with a reported selectivity 
ratio of > 6 and acceptable 50% haemolytic dose (HD50 of 100 
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µM).
23
 However, more recently, another publication reports in 
vitro mammalian assays and observed toxicity of peptoid 13 at 
5.1 µM against NIH 3T3 murine fibroblasts.
37
 The Olsen group 
have also demonstrated that α-peptide β-peptoid hybrids 
show negligible haemolytic activity, but cause severe 
membrane alterations to human erythrocytes at low 
concentrations via microscopy.
31
 Therefore, there is a clear 
need to scrutinise the relationship between peptoid 
antimicrobial activity and their toxicity towards mammalian 
cells in greater detail.  
In this study we report the synthesis of one of the largest 
single library of antimicrobial peptoids published to date, in 
order to undertake a structure-activity relationship (SAR) of 
the wide variety of chemical functionalities present. Some of 
the sequence motifs and monomers represented here have 
not yet been reported in any antibacterial peptoids. This study 
focuses on the antibacterial potency of these peptoids against 
representative Gram-positive and Gram-negative species and 
significantly, we also examine the toxicity of this library using 
therapeutic indices against representative mammalian cell 
lines to evaluate the potential of peptoids as novel anti-
infective compounds. 
Results and Discussion 
Library Design 
We previously described the antiparasitic activities of a small 
library of linear peptoids.
33
 In this work, 18 peptoids from this 
first library have been retested to investigate their 
antibacterial activity and toxicity profiles (peptoids 1-18, Table 
1), which to date have not been reported. An additional 26 
novel peptoids were also synthesised to conduct a broader 
SAR study (peptoids 19-44, Table 1). This library represents the 
largest library of anti-infective peptoids published to our 
knowledge.  
Since the presumed mode of action of AMPs is by 
membrane disruption, the peptoid sequences selected contain 
a variety of side chain functionalisation to help elucidate the 
features necessary for activity. A defined secondary structure 
is thought to promote the antimicrobial action of both 
peptoids and peptides, therefore all peptoids tested here were 
designed around a repeating trimer motif where the third 
monomer was typically a cationic monomer (a peptoid helix 
turn is reported to occur every three residues in a polyproline 
type I helix) and often included the α-chiral Nspe or N(S-
phenylethyl) glycine monomer in order to help induce an 
amphipathic secondary structure.
23,38
 
All peptoids were either synthesised manually on-resin or 
using an automated synthesiser using the submonomer 
method of synthesis at room temperature. Compounds 
between six and twelve residues in length were made, 
corresponding to peptoids with an overall positive charge of 
+2, +3 or +4.
39,40
 This extended library includes a wide range of 
monomers, such as those containing alkyl and substituted 
aromatic residues, including chlorinated and fluorinated 
peptoids. In addition, we have included peptoids that have 
different cationic functionalities in the sequence to further 
probe the relationship between charge and activity (Figure 2). 
Previously we described the activity of peptoids that 
contain lysine monomers (amino-functionalised cationic 
residues).
32,33
 It has been suggested that arginine-containing 
peptoids may have increased membrane permeability
41
 and so 
a small number of arginine analogues of our lysine library were 
generated. In addition, we recently described the synthesis of 
peptoids with mixed lysine and arginine functionalities, which 
are some of the first examples of this class of compound to be 
reported in the literature.
42
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Peptoid monomers utilised in this study. 
 
Antimicrobial Activity 
The activity of our peptoid library was assessed against both 
bacterial and mammalian cells to gain a broader 
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understanding of the factors that lead to effective and 
selective antimicrobial peptoids. We screened for broad-
spectrum antibacterial activity against Gram-negative 
(Escherichia coli and Pseudomonas aeruginosa) and Gram- 
positive (Staphylococcus aureus and S. epidermidis) bacteria. 
The toxicity of the library was also assessed against two 
mammalian cell lines; HaCaT spontaneously transformed 
aneuploid keratinocytes were employed to model toxicity 
against human skin cells and HepG2, a cell line derived from a 
human liver carcinoma, were used as a study on polarised 
human hepatocytes. Detailed methods for these assays can be 
found in the Supplementary Information. 
In order to compare the activity of our compounds 
between the minimum inhibitory concentration (MIC) values 
obtained for bacteria and the effective dose (ED50) 
measurements against eukaryotic cells, all results have been 
presented in µM units. As seen from the data summarised in 
Table 1, many peptoids within the library have low MIC values 
against both Gram-negative and Gram-positive bacteria, 
ranging from the most active at less than 1 µM to inactive 
peptoids with no activity even at 100 µM. Some of the MIC 
values obtained are within the same range of selected natural 
antimicrobial peptides described in the literature. For example, 
the AMP cecropin A was shown to kill 90% of E. coli at 2 µM
43 
and peptoids 33, 34, 35 and 37 all have an MIC of 6 µM against 
E. coli. Magainin 2, an amphibian derived AMP, was reported 
to have MICs against E. coli, S. epidermidis and S. aureus of 5 
µg/mL (2 µM), 10 µg/mL (4 µM) and 50 µg/mL (20 µM) 
respectively and many of the peptoids in Table 1 exhibit even 
better antibacterial activities.
43,44
 
Unsurprisingly, the activity of most of the peptoids is 
significantly greater against the Gram-positive species (S. 
aureus and S. epidermidis) than the Gram-negative E. coli and 
P. aeruginosa. This differential activity is probably due to the 
presence of the lipopolysaccharide-rich outer membrane of 
Gram-negatives, which presents a significant permeability 
barrier to many hydrophobic molecules.
45,46
 Certain 
compounds within the library displayed selectivity for 
particular bacterial species, For example, compound  17 had 
an MIC of 25 µM against E. coli, but > 100 µM against the other 
Gram-negative bacterium, P. aeruginosa or 20 which has an 
MIC of 6 µM against S. epidermidis but only moderate activity 
of 25 µM against S. aureus. However, no Gram-negative 
specific antibacterial peptoids were identified. Any sequences 
that can selectively target Gram-negative bacteria are highly 
sought after due to rising concerns over antibiotic 
resistance.
47-49
  
 
Structure-activity relationships: Simple Library 
Factors necessary for robust activity against the protozoan 
intracellular parasite Leishmania mexicana were previously 
determined and include sequence length and inclusion of 
chiral monomers.
31
 Side chain length of cationic residues was 
also identified as an important feature for efficacy, with Nae or 
NLys displaying improved antiparasitic activity over the longer 
Nah residue.
33
  The same features are replicated here in the 
activity of the peptoid library against differing bacterial 
species. The longest 12 residue peptoids (1, 4, 7, 10, 13 and 
16) were always more active than their 9 residue analogues (2, 
5, 8, 11, 14 and 17), which were themselves more active than 
the 6 residue sequences (i.e. 3, 6, 9, 12, 15 and 18), 
conclusions that agree with those from the Barron group.
23
 
Hexapeptoids 3, 6, 9, 12, 15 and 18 showed generally limited 
antibacterial activity against the bacteria tested with MICs of 
100 µM, although it is interesting to note that S. epidermidis 
did show some increased sensitivity to peptoids 12 and 15 
(Table 1).  
Interestingly, the effect of monomer chirality was less 
important than with L. mexicana in achieving antibacterial 
activity; in many cases, sequences comprised exclusively from 
achiral monomers had comparable or better activity than 
analogues containing the chiral Nspe building block. For 
example, comparing peptoid 4 to 13 which are achiral and 
chiral analogues of the same sequence, we observe similar 
MIC values against P. aeruginosa (50 µM for both) and S. 
aureus (MIC 3 µM and 2 µM). However, against E. coli, the 
achiral peptoid 4 has an MIC of 12 µM compared to 25 µM for 
the chiral equivalent 13. A similar pattern is apparent with 
peptoids 7 and 16 (sequences with Nae and either Nphe or 
Nspe respectively), with the peptoids having similar activity 
against both P. aeruginosa and S. aureus but the achiral 
sequence 7 shows better activity against E. coli (MIC 13 µM 
and > 100 µM respectively). 
When comparing sequences containing different amino-
functionalised cationic monomers, Nae, NLys and Nah, it is not 
possible to draw a simple conclusion about the optimum 
length of side chain for best antibacterial activity since 
promising activity is evident with all three cationic residues. 
Peptoids based upon the NxNpheNphe motif 1 (Nah), 4 (NLys) 
and 7 (Nae) all have an MIC of 13 µM against E. coli and good 
activity against both Staphylococcus species. However, when 
comparing the chiral analogues of the same motif (Nspe 
replaced Nphe), the sequences with Nah and NLys (10 and 13) 
have an MIC of 25 µM against E. coli but the peptoid with the 
shortest Nae residue (16) has negligible activity. For peptoids 
10, 13 and 16, the activity against P. aeruginosa, S. aureus and 
S. epidermidis is similar regardless of the choice of cationic 
monomer (Table 1). 
 
Effects of aromatic building block substitution 
A selection of substituted aromatic monomers were included 
in a similar repeating motif of two aromatic monomers 
followed by the charged NLys residue to determine their 
impact on biological activity. Monomer substitutions included 
a methoxy group (Npmb), chlorine (Npcb) or fluorine in both 
para and meta positions (Npfb, Nmfb). The effect of these 
substitutions on anti-Leishmanial activity were reported 
recently.
32
 It was shown that halogenated monomers (in 
particular fluorinated ones) improve the efficacy of peptoid 
sequences against amastigotes. Based upon the success of this 
approach, we concentrated our efforts on the antibacterial 
screening of halogenated sequences. 
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Methoxy substituted peptoids were only tested at the 
longest 12 residue length (peptoid 19) and show a negligible 
effect against the two Gram-negative species and no 
improvement in action against the Gram-positive bacteria 
compared to the unsubstituted analogue (peptoid 4).  Addition 
of chlorine in the para position improves activity against L. 
mexicana axenic amastigotes, however decreases antibacterial 
activity (i.e. compounds 20 cf 4 with an MIC of >100 µM and 13 
μM with E. coli) and also significantly increases the toxicity of 
the sequences to mammalian cells (ED50 HepG2 22 μM and > 
100 µM respectively).   
Fluorinated peptoid sequences were more successful at 
targeting the various bacteria. Peptoids with exclusively achiral  
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Table 1: Toxicity, antibacterial activity and associated selectivity values for the compounds studied. Selectivity is represented as an average of the selectivity to HaCaT 
and HepG2 (where selectivity = toxicity/activity). All data and unaveraged selectivity values can be found in the ESI. ND – compounds were not tested due to a lack of 
material, but are included here as some data was collected against certain species and they represent novel peptoid structures. References show publications where 
the same sequences have previously been evaluated for their antimicrobial activity. 
 
Peptoid Sequence Ref. ED50 (µM) MIC (µM) Average Selectivity 
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(NahNpheNphe)4 1 
33
 > 100 > 100 13 > 100 2 6 8 1 50 17 
(NahNpheNphe)3 2 
33
 > 100 > 100 50 > 100 6 3 2 1 17 33 
(NahNpheNphe)2 3 
33
 > 100 > 100 > 100 > 100 > 100 > 100 1 1 1 1 
(NLysNpheNphe)4 4 
33,37
 36 > 100 13 50 3 2 6 2 23 34 
(NLysNpheNphe)3 5 
33
 > 100 > 100 50 > 100 25 6 2 1 4 17 
(NLysNpheNphe)2 6 
33
 > 100 > 100 > 100 > 100 > 100 > 100 1 1 1 1 
(NaeNpheNphe)4 7 
33
 > 100 > 100 13 50 2 6 8 2 50 17 
(NaeNpheNphe)3 8 
33
 > 100 > 100 > 100 > 100 13 > 100 1 1 8 1 
(NaeNpheNphe)2 9 
33
 > 100 > 100 > 100 > 100 > 100 > 100 1 1 1 1 
(NahNspeNspe)4 10 
33
 23 41 25 50 2 2 2 1 16 17 
(NahNspeNspe)3 11 
33
 > 100 > 100 25 > 100 3 2 4 1 33 50 
(NahNspeNspe)2 12 
33
 > 100 > 100 > 100 > 100 > 100 25 1 1 1 4 
(NLysNspeNspe)4 13 
21,23,33
 20 29 25 50 2 1 1 1 13 25 
(NLysNspeNspe)3 14 
23,33
 > 100 > 100 13 > 100 2 2 8 1 50 50 
(NLysNspeNspe)2 15 
23,33
 > 100 > 100 > 100 > 100 > 100 25 1 1 1 4 
(NaeNspeNspe)4 16 
33
 26 41 > 100 50 2 2 0 1 17 17 
(NaeNspeNspe)3 17 
33
 > 100 > 100 25 > 100 2 13 4 1 50 8 
(NaeNspeNspe)2 18 
33
 > 100 > 100 > 100 > 100 > 100 > 100 1 1 1 1 
(NLysNpmbNpmb)4 19  41 > 100 > 100 > 100 3 2 1 1 24 36 
(NLysNpcbNpcb)4 20  18 22 > 100 > 100 25 6 0 0 1 4 
(NLysNpcbNpcb)3 21  22 23 50 25 3 2 0 1 8 12 
(NLysNpfbNpfb)4 22  46 30 13 25 2 1 3 2 19 38 
(NLysNpfbNpfb)3 23  > 100 45 13 25 3 3 6 3 24 24 
(NLysNmfbNmfb)4 24  25 17 25 25 6 3 1 1 4 7 
(NLysNmfbNmfb)3 25  64 43 13 25 6 2 4 3 9 27 
(NLysNpfbNspe)4 26  20 26 13 13 2 2 2 2 12 12 
(NLysNpfbNspe)3 27  52 36 25 25 3 2 2 2 15 22 
[(NLysNpfbNpfb)(NLysNspeNspe)]2 28  > 100 55 6 50 2 1 13 2 39 78 
(NLysNspeNspe)(NLysNpfbNpfb)(NLysNspeNspe) 29  65 43 13 25 3 2 4 3 21 28 
(NamyNspeNspe)[(NLysNspeNspe)]3 30  12 15 50 50 2 2 0 0 7 7 
(NamyNspeNspe)2(NLysNspeNspe)2 31  20 18 > 100 > 100 2 1 0 0 10 19 
(NLysNspeNspe)2(NamyNspeNspe)(NLysNspeNspe) 32  20 22 > 100 > 100 6 2 0 0 4 11 
(NhArgNpheNphe)4 33  > 100 ND 6 25 ND 2 17 4 - 50 
(NhArgNspeNspe)4 34  20 12 6 13 1 1 3 2 16 16 
(NhArgNspeNspe)3 35  ND ND 6 50 2 2 - - - - 
(NhArgNmfbNmfb)4 36  28 21 13 13 2 2 2 2 12 12 
(NhArgNmfbNmfb)3 37  ND ND 6 25 2 1 - - - - 
(NhArgNhLeuNspe)4 38  ND ND 13 25 1 2 - - - - 
(NhArgNhLeuNspe)3 39  ND  ND ND > 100 3 2 - - - - 
[(NamyNspeNspe)(NhArgNspeNspe)]2 40  31 24 > 100 > 100 3 6 0 0 9 5 
(NLysNspeNspe)2(NhArgNspeNspe)2 41  > 100 ND 17 34 17 ND 6 3 6 - 
(NhArgNspeNspe)2(NLysNspeNspe)2 42  15 ND 17 17 17 ND 1 1 1 - 
(NLysNspeNspe)(NhArgNspeNspe)(NLysNspeNspe)2 43  33 ND 17 17 17 ND 2 2 2 - 
[(NhArgNspeNspe)(NLysNspeNspe)]2 44  33 ND 17 67 17 ND 2 0 2 - 
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monomers (Npfb or Nmfb) and those with a mixture of chiral 
and achiral building blocks (Npfb and Nspe) were tested. Those 
sequences containing the achiral monomers (peptoids 22 – 25) 
have marginally improved antibacterial activities compared to 
analogues of the same length with Nphe rather than 
fluorinated monomers (peptoids 4 – 6). There seems to be no 
significant difference between monomers substituted in the 
para or meta position. Interestingly, the 9-residue peptoids 23 
and 25 have a similar level of broad spectrum antibacterial 
activity as those with 12 residues (22 and 24), but the former 
show reduced toxicity to mammalian cells. The 6-residue 
sequences display reduced activity against bacteria. In this 
case, it appears that the shorter 9-residue sequences 23 and 
25 may prove to be better antibacterial candidates with a 
larger therapeutic window between activity and toxicity (Table 
1). 
The simple chiral sequences (i.e. 13) are more potent, but 
also more toxic than the achiral Nphe peptoids (4 – 6). Given 
that the fluorinated, achiral monomers exhibit an increase in 
antibacterial activity compared to the unsubstituted 
analogues, the Npfb monomer was also placed into the 
following motif: NLysNpfbNspe to examine whether the 
activity of chiral sequences could be modulated (peptoids 26 
and 27). Further iterations were also synthesised where the 
Npfb and Nspe monomers were placed in a coblock manner 
(i.e. sequences 28 and 29). In both templates, the longest 
sequences showed the best broad-spectrum antibacterial 
activity. In particular, the 12-residue block peptoid (28) is 
promising, with reduced toxicity compared to sequences made 
of Nspe or Npfb exclusively and improved activity against E. 
coli (MIC 6 µM), S. aureus and S. epidermidis (MICs 2 µM and 
<1 µM). 
 
Peptoids containing alkyl chains 
To probe the relationship between net charge and 
hydrophobicity of a peptoid and its biological activity, 
analogues of peptoid 13 were synthesised where the cationic 
NLys monomer was substituted by the alkyl monomer Namy. 
By replacing the charged amino group with a methyl group, 
the overall compound charge is reduced, however the number 
of atoms in the side chain and overall molecular weight 
remains unaltered. In these analogues (peptoids 30 – 32), the 
charge is replaced at just the N terminal end of the sequence 
or at two positions within the sequence.  
When the antibacterial properties are considered, there is 
little difference in efficacy against the Gram-positive bacteria 
tested, however, the substitutions lead to a reduction in 
overall activity against Gram-negatives. The parent sequence 
13 shows moderate activity against E. coli and P. aeruginosa 
(MICs of 25 µM and 50 µM respectively) and potent 
micromolar activity against the Gram-positives. However, 
peptoids 30 - 32 have MICs of 50 µM or >100 µM against E. coli 
and similar reductions in activity are seen for P. aeuriginosa.  
 
Substitution of arginine- instead of lysine-residues 
As described in the literature
31,41,50
, arginine-containing 
peptoids are known to increase membrane permeability and 
antibacterial activity. Hence, sequences containing arginine 
peptoid monomers were included in the library. This allowed 
the comparison of differently functionalised cationic residues 
on the peptoid sequences (i.e. the amino NLys peptoids or the 
guanidine groups of NhArg). It has also been suggested that 
arginine in peptide sequences can improve antibacterial 
potency, although this is also linked with enhanced 
toxicity.
26,31
 In an attempt to modulate the biological 
properties of the peptoid library, for the first time, peptoids 
with both lysine and arginine in the same sequence were 
evaluated against bacterial targets using the new methodology 
developed in our group.
42
 
This sublibrary of peptoids can be split between sequences 
exclusively containing arginine residues (peptoids 33 – 40) and 
those that contain a mixture of both lysine and arginine-type 
side chains (peptoids 41 – 44). In these compounds NhArg was 
introduced, which is the equivalent side chain to the NLys 
residue, with 4 carbons in the backbone and the terminal 
guanidine moiety.  
In contrast to peptoids that contain amino-functionalised 
NLys residues the NhArg sequences tend to have an increased 
toxicity to the mammalian cell lines tested but do also display 
improved activity against the bacteria tested.  For example, 
when comparing the fluorinated peptoids 36 and 37 to their 
lysine-equivalents (24 and 25 respectively) we see an 
approximate 2-fold increase in antibacterial activity for all 
species tested; for the longest 12-residue sequence 
(NxNmfbNmfb)4 activity against E. coli is 13 μM in 36 with 
NhArg, compared to 25 μM in 24 (NLys). Against S. aureus the 
arginine-type peptoid has an MIC of 2 μM contrasting with 6 
μM for the lysine equivalent. However, in sequences that were 
inactive with lysine residues, replacement by NhArg does not 
make the sequence active (see peptoid 40, where the 
sequence is not active against Gram-negative bacteria at any 
concentration), but in these cases the inclusion of the 
guanidine group does increase the toxicity. 
As predicted, sequences with a combination of lysine and 
arginine-type residues show a balance between toxicity to 
mammalian cells and antibacterial activity compared to 
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Figure 3: Antibacterial activity of peptoids plotted against the average toxicity to mammalian cell lines (HaCaT and HepG2). A: E. coli, B: P. aeruginosa, C: S. aureus, D: 
S. epidermidis. Compounds indicated in green show activity against prokaryotes with reduced toxicity to eukaryotes, those in red show increased toxicity to 
mammalian cells and/or weaker activity against the bacteria. 
sequences containing NLys or NhArg residues exclusively. For 
example, in related peptoids containing all arginine residues
(34), all lysine residues (13) and both lysine/arginine 
monomers within the same sequence (peptoids 42 - 44), we 
see toxicity to the HaCaT keratinocytes at 11 μM, 20μM and 
15-33 μM respectively.  The general antibacterial activity 
follows a similar trend, for example, against E. coli the lysine-
only peptoid 13 has the lowest activity at 25 µM, the arginine-
only peptoid 34 has the most potent activity with an MIC of 6 
µM and the mixed sequences 42 - 44 have intermediate 
activity at 17 µM.  
The observation that guanidine-only peptoids display the 
most potent biological activities is in agreement with previous  
studies into arginine-rich peptides, which are able to bind 
membrane-bound lipids more readily than their amino-
functionalised lysine equivalents.
31,51
 In this case it was 
proposed that the arginine-type side chains can form 
bidentate hydrogen bonds with the phospholipid head groups. 
This conclusion was also reached in studies with antimicrobial   
peptide-peptoid hybrids containing both lysine and 
arginine.
31,51
 
 
Toxicity 
From the antibacterial MIC determination in Table 1, multiple 
promising peptoids were identified that showed little or no 
toxicity to either of the mammalian cell lines tested. For 
example, compounds 4, 7, 23 and 28 display negligible toxicity 
to HaCaT or HepG2 at the highest concentrations used and are 
also broad spectrum antibacterial agents. However, many of 
the sequences generated did display significant toxicity to 
mammalian cells, and in general these compounds were 
similarly toxic to both HaCaT and HepG2. On the whole, as the 
antimicrobial action of a compound increases, the associated 
toxicity is also increased. This is a problem found in other 
recent studies that focused on the biological applications of  
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Figure 4. Antibacterial activity of peptoids plotted against HPLC retention times. A: E. coli, B: P. aeruginosa, C: S. aureus, D: S. epidermidis. The HPLC gradient from 0-
100% B was conducted over 30 minutes with a column oven at 40 ˚C, where solvent A was 95% H2O, 5% MeCN, 0.1% TFA and solvent B was 95% MeCN, 5% H2O, 0.1% 
TFA. Peptoids, shown in green, show antibacterial activity, those in black have negligible activity. 
peptoids, however, attention is frequently not directed 
towards the issue of toxicity.
26,29,37
  
The selectivity of sequences is highlighted as a particular 
challenge for the design of antimicrobial peptoids. To explore 
the relationship between activity and toxicity a comparison 
was made between the MIC values against each bacterial 
species versus the average toxicity of each peptoid to HaCaT 
and HepG2 (see Figure 3). 
A handful of peptoids were identified that show 
respectable antibacterial activity and also display low toxicity 
to mammalian cells. These compounds have the potential to  
be future selective antibiotic compounds. However, a large 
proportion of the peptoids within this library do display 
significant toxicity. There are also many sequences that are 
toxic to mammalian cells, but show little activity against Gram-
negative bacteria. It is likely that the external 
lipopolysaccharide layer on the outer membrane of both E. coli 
and P. aeruginosa (absent in Gram positive bacteria) prevents 
these peptoids from reaching the cell membrane. To 
investigate a possible explanation for this observation, the 
hydrophobicity of the compounds was considered. 
 
Hydrophobicity 
The hydrophobicity of our library was assessed using reverse-
phase HPLC retention times as in Figure 4. Although this 
provides only a relatively crude measure of hydrophobicity and 
may not translate directly into predictions about how a 
compound will interact with the cell membranes of biological 
systems, certain interesting trends were evident from the 
analysis.  
Since the activity of peptoids is much greater against Gram-
positive bacteria than Gram-negative bacteria, the graphs are 
predominantly populated by peptoids for E. coli and P. 
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aeruginosa due to their higher MIC values. There appears to 
be a linear relationship between activity and retention time for 
the Gram-positive bacteria, where the peptoids at longer 
retention times (therefore more hydrophobic) have the lowest 
MIC values against S. aureus or S. epidermidis.  
However, for the Gram-negative bacteria, there is no clear 
correlation between hydrophobicity and antibacterial activity 
of the peptoid library. Some compounds with the longest 
retention times (presumably the most hydrophobic) are 
inactive against these bacteria, whereas others with shorter 
retention times display good activity. It has previously been 
suggested that highly hydrophobic sequences may have lower 
activities due to self-association, preventing sufficient contact 
with the cell membrane.
29
 However, this may be an 
oversimplification since the same results are not observed 
with Gram-positive bacteria, where the same hydrophobic 
peptoid sequences result in low MIC values. 
The discovery that peptoids with high hydrophobicity are 
not always the most potent against E. coli and P. aeruginosa, 
but against S. aureus a linear relationship is seen between 
hydrophobicity and activity is corroborated by a recent 
report.
29
 However, the lack of a consensus between 
hydrophobicity and activity in published libraries, highlights 
the need for the research community to develop additional 
tools to help predict peptoid properties and likely efficacy.  
There also seems to be a correlation between the toxicity 
of our peptoid library to mammalian cells and compound 
hydrophobicity, with a similar profile of toxicity for both HaCaT 
and HepG2 (see Figure 5). The least hydrophobic compounds 
are generally the least toxic, whereas those with the highest 
retention times show the lowest ED50 values. 
In the literature, HPLC retention times are used to 
rationalise antimicrobial activity
21,23,29
 and also for in silico 
predictions of activity.
37
 From the data presented here, it is 
suggested that HPLC retention time alone cannot estimate or 
rationalise activity. For Gram-negative bacteria, HPLC 
retention time is not predictive of activity and although 
peptoids with longer retention times may have an increased 
efficacy against Gram-positive bacteria, these compounds may 
also have a concomitant and undesirable increased toxicity. 
Other parameters to evaluate the activity of antimicrobial 
peptiods and guide the design of bioactive peptoids need to be 
considered. We recently proposed hydrophobicity 
measurements determined via partitioning experiments (i.e. 
log D) as an improved approach to rationalise the biological 
activity of peptoids.
52
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Peptoid toxicity plotted against HPLC retention time. HPLC gradient 
from 0-100% B over 30 minutes, column oven at 40 ˚C, where solvent A is  95% 
H2O, 5% MeCN, 0.1% TFA and solvent B is 95% MeCN, 5% H2O, 0.1% TFA. 
Compounds indicated by green show negligible toxicity, those in red show 
toxicity to mammalian cells. 
Conclusions 
This study presents a large and varied library of peptoids that 
were specifically designed to mimic natural antimicrobial 
peptides. Many of the peptoids generated show potential as 
antimicrobial compounds, with broad-spectrum activity 
against a wide variety of bacterial and parasitic targets and 
may be promising leads in the future for antibiotics that can 
combat the increasing problem of resistance. 
Most of the peptoids were considerably more active 
towards Gram positive species than Gram-negatives in keeping 
with their differing envelope structures. Hence the peptoid 
library has much better therapeutic indices against S. aureus 
and S. epidermidis. The best activity against E. coli reported 
was 6 µM for peptoids 28, 33, 34, 35 and 37 and 13 µM against 
P. aeruginosa for peptoids 26, 34 and 36. Many peptoids also 
showed micromolar activities against S. aureus and S. 
epidermidis with both species showing a similar pattern of 
sensitivity; S. aureus did show a tendency to be more resistant 
than S. epidermidis possibly due to minor differences in cell 
surface charge and hydrophobicity.
53,54
 In many cases, P. 
aeruginosa also proved more peptoid-resistant than E. coli. 
This difference may reflect variation in lipid composition or the 
capacity of P. aeruginosa to form biofilms and has been 
observed previously with AMPs, such as LL-37.
55
 
Factors contributing to enhanced antimicrobial activity 
include the overall length of sequence, with longer, 12-residue 
peptoids typically displaying the best activity, although in 
many cases the 9-residue peptoids also display broad 
spectrum activity against bacteria. Substitution of fluorine in 
peptoid monomers also enhances activity and in many cases, 
achiral sequences displayed potency, especially against the 
Gram-positive species. Interestingly, from our library most 
compounds that are active against the bacteria but exhibit 
no/low toxicity to mammalian cells contain achiral monomers, 
or at least a reduced frequency of chiral monomers within the 
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sequence compared to the standard NxNspeNspe motif. 
Whether through the presumed increase in hydrophobicity, or 
through other effects, the addition of chiral Nspe residues in a 
sequence often has a detrimental effect on overall toxicity. 
Since many of the achiral sequences show potent antibacterial 
activity and these peptoids are not expected to form fully 
folded peptoid helices, secondary structure is perhaps not as 
important as predicted. 
It is generally stated that the mode of action for 
AMPs/peptoids is cell membrane disruption.
47,56,57
 For certain 
compounds, particularly the more hydrophobic compounds 
that are both active and toxic, this may be the case. However, 
the differences exhibited by some compounds, particularly 
those with negligible toxicity to mammalian cells yet good 
activity against bacteria, may indicate that cell membrane 
disruption is not the only mechanism at work.
46
 Current work 
within our group is now focussing on investigating the 
molecular mechanism of a selection of these compounds to 
elucidate the factors necessary for antimicrobial selectivity and 
potency. 
The peptoid community clearly has the requisite tools to 
design and synthesise effective antimicrobial peptoid 
sequences with potential for clinical application, however, the 
challenge now is to focus on increasing pathogen selectivity 
while minimising host cell toxicity.  
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Experimental 
Materials and Reagents 
Abbreviations for reagents are as follows: tert-butoxycarbonyl 
(Boc); 9-fluorenylmethoxylcarbonyl (Fmoc); trifluoroacetic acid 
(TFA); triisopropylsilyl (TIPS); N,N-dimethylformamide (DMF); 
N,N-diisopropylcarbodiimide (DIC); dimethylsulphoxide 
(DMSO). Solvents and reagents were purchased from 
commercial sources and used without further purification 
unless otherwise stated. Rink amide resin (typical loading level 
0.6-0.8 mmol g
-1
) was purchased from Merck4Biosciences. 
DMF was purchased from AGTC Bioproducts (National 
Diagnostics). Piperidine, bromoacetic acid and TFA were 
purchased from Sigma Aldrich. The amine building blocks were 
sourced from Sigma Aldrich or TCI Europe. 
Peptoid Synthesis Procedures  
Peptoids in this library were synthesised both manually and on 
an automated synthesiser. Protocols for each synthesis 
method follow. 
 
Manual Linear Peptoid Synthesis: 
Fmoc-protected Rink Amide resin (normally 100 mg, 0.1 mmol, 
typical loading between 0.6–0.8 mmol g
-1
) was swollen in DMF 
(at least 1 h at room temperature, overnight preferred) in a 20 
mL polypropylene Bond Elut SPPS cartridge fitted with two 
polyethylene frits (Crawford Scientific). The resin was 
deprotected with piperidine (20% in DMF v/v, 2 x 20 min) and 
washed with DMF (3 x 2mL). The resin was treated with 
bromoacetic acid (1mL, 0.6M in DMF) and DIC (0.2 mL, 50% v/v 
in DMF) for 20 min at room temperature on a shaker platform 
at 400 rpm (Radleys Technology). The resin was washed with 
DMF (3 x 2 mL), before the desired amine sub-monomer was 
added (1 mL, 1.5M in DMF) and allowed to react for 60 min on 
the shaker. The resin was again washed with DMF (3 x 2 mL) 
and the bromoacetylation and amine displacement steps were 
repeated until the final sub-monomer had been added and the 
desired peptoid sequence obtained. Resin was washed with 
DCM and the final cleavage from resin was achieved using a 
TFA cleavage cocktail (4 ml; TFA:TIPS:H2O, 95:2.5:2.5) on the 
shaker at 400 rpm for 60 min. The resin was removed by 
filtration and the cleavage cocktail removed in vacuuo. The 
crude product was precipitated in diethyl ether (30 mL) and 
the precipitate retrieved by centrifuge for 15 min at 5,000 
rpm. The ether phase was decanted and the crude product 
dissolved in a mixture of acidified H2O and MeCN and 
lyophilised to a powder before purification.  
 
Automated Linear Peptoid Synthesis: 
Automated peptoid synthesis using an Aapptec Apex 396 
synthesiser. Fmoc-protected Rink Amide resin (0.1 mmol, 
loading 0.54 mmol g
-1
) was swollen in DMF (2 mL, 2 min, 475 
rpm at RT) and deprotected with 4-methylpiperidine (20% in 
DMF v/v, 1 mL for 1 min, 475 rpm at RT; then 2 mL for 12 min, 
475 rpm at RT). The resin was treated with haloacetic acid 
solution (either bromo- or chloroacetic acid, 1 mL, 0.6M in 
DMF) and DIC (0.18 mL, 50% v/v in DMF) for 20 min at 475 
rpm, RT. The resin was washed with DMF (2 mL DMF for 1 min 
at 475 rpm, x 5) before the desired amine sub-monomer was 
added (1 mL, 1.5M in DMF) and shaken for 60 min at 475 rpm. 
The resin was washed again with DMF (2 mL DMF for 1 min at 
475 rpm, x 5) and the acetylation and amine displacement 
steps were repeated until the desired sequence was achieved. 
The resin was shrunk in diethyl ether and peptoids cleaved off 
the resin using a TFA cleavage cocktail (4 ml; TFA:TIPS:H2O, 
95:2.5:2.5) for 30-60 min on an orbital shaker at 250 rpm, RT. 
The cocktail was filtered from the resin and evaporated in 
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vacuuo and the resulting residue precipitated in diethyl ether 
(~20 ml). The crude peptoid was obtained via centrifugation 
(15 min, 4,000 rpm, 5 ˚C) and the ether layer decanted to yield 
the crude product as a powder. Peptoids were lyophilised 
before purification by semi-preparative RP-HPLC.  
 
Addition of NhArg and NnArg residues to sequence: 
To introduce arginine-type residues during the submonomer 
procedure, the appropriate unprotected diamine was added 
under normal submonomer coupling conditions (1.5M amine 
in DMF, 60 min, room temperature) in place of the mono N-
Boc diamine and the resin washed with DMF (3 x 2mL). Dde-
OH (10 eq. wrt resin in the minimum volume of DMF) was 
added to the resin and placed on the shaker at RT for 60 min 
and the resin washed well with DMF (3 x 2mL). Subsequent 
peptoid couplings were made as normal until the desired 
sequence was achieved, including any extra Dde-protected 
residues. 
 
After synthesis of the linear peptoid sequence, on resin 
deprotection of the Dde group was undertaken using 2% 
hydrazine in DMF (4 x 4ml x 3 min) and the resin washed with 
DMF (3 x 2 mL). Guanidinylation of the free amines was 
achieved using pyrazole-1-carboxamide (6 eq. per free amine, 
in the minimum amount of DMF) and DIPEA (6 eq. per free 
amine) on the shaker at 400 rpm, RT for 60 min. The resin was 
washed with DCM (3 x 2 mL) and shrunk in ether prior to 
cleavage from the resin, as above. 
Purification by preparative RP-HPLC 
Preparative RP-HPLC was performed with a semi-preparative 
Perkin Elmer Series 200 lc pump fitted with a 785A UV/Vis 
detector using a SB-Analytical ODH-S optimal column (250 × 10 
mm, 5 µm); flow rate 2 ml min
−1
; λ = 250 nm, where a linear 
gradient from solvent A to B applied (A = 0.1% TFA in 95% H2O 
and 5% MeCN, B = 0.1% TFA in 5% H2O and 95% MeCN).  
 
Characterisation 
Peptoids were characterised by accurate LC-MS (QToF mass 
spectrometer and an Acquity UPLC from Waters Ltd) using an 
Acquity UPLC BEH C8 1.7μm (2.1mm × 50mm) column with a 
flow rate of 0.6 ml min
-1
 and a linear gradient of 5-95% of 
solvent B over 3.8 min (A = 0.1% formic acid in H2O, B = 0.1% 
formic acid in MeCN). Peptide identities were also confirmed 
by MALDI-TOF mass spectra analysis (Autoflex II ToF/ToF mass 
spectrometer Bruker Daltonik GmBH) operating in positive ion 
mode using an α-cyano-4-hydroxycinnamic acid (CHCA) matrix. 
Data processing was done with MestReNova Version 8.1. 
 
Analytical RP-HPLC was carried out using a Perkin Elmer Series 
200 lc pump fitted with a series 200 UV/Vis detector and 
autosampler using a SB-Analytical ODH-S optimal column (100 
× 1.6 mm, 3.5 µm); flow rate 1 ml min
−1
; λ = 220 nm, linear 
gradient elution 0-100% of solvent B over 30 min (A = 0.05% 
TFA, 95% H2O, 5% MeCN, B = 0.03% TFA, 5% H2O, 95% MeCN). 
 
Biological Assays 
Antibacterial MIC determination 
Please note – ED50, the median effective dose, was defined as the 
dose that kills 50% of cells. 
 
Escherichia coli K-12 wild-type strain (W3110 / ATCC27325, F
-
, 
λ
-
, rpoS(Am), rph-1, Inv(rrnD-rrnE)), Pseudomonas aeruginosa 
PA01 (ATCC 15692) Staphylococcus aureus (3R7089 strain 
Oxford / ATCC9144) and Staphylococcus epidermidis 
(laboratory strain from clinical isolate) were selected for 
bacteriological studies as representative Gram-negative (E. coli 
and P. aeruginosa) and Gram-positive (S. aureus and S. 
epidermidis) species. Bacterial cultures were prepared by 
streaking bacterial strains onto LB agar plates with an 
inoculation loop and incubated overnight at 37 °C. A single 
colony was selected and placed in 5 mL of Iso-sensitest broth 
(Oxoid, ThermoScientific) and incubated with shaking for 16-18 
h at 37 °C to provide liquid cultures for testing.  
 
MIC values were obtained according to the protocol described 
by J. M. Andrews et al.
58
 and were conducted in 96-well plates 
(Sarstedt). Bacteria were grown from overnight cultures in  Iso-
sensitest broth to an A650nm of 0.07 equivalent to a 0.5 
MacFarland standard (240 μM BaCl2 in 0.18 M H2SO4). This 
culture was diluted ten-fold with Iso-sensitest broth before 
use. Peptoids were initially dissolved in DMSO (5 mM) and 
diluted further in Iso-sensitest broth to achieve a 
concentration range of 4 – 200 µM using 2-fold serial dilutions. 
50 μl of inoculum and 50 μl of peptoid solution were added to 
each test well (final concentration range of 2 – 100 µM). 
Experiments were performed in triplicate. A positive control 
for bacterial growth contained only the inoculum and Iso-
sensitest broth. Other controls contained the inoculum and 
serial dilutions of ampicillin (from 250 µg/mL to 2 µg/mL), 
serial dilutions of DMSO and the inoculum to confirm no 
inhibitory effect on bacterial growth, and Iso-sensitest broth 
alone as a sterile control. The MIC was defined as the lowest 
concentration which completely inhibited bacterial growth 
after incubation at 37 °C for 16 h with shaking. Quantitative 
data was attained from absorbance values using a Biotek 
Synergy H4 plate reader. 
 
Cytotoxicity assay with HepG2 or HaCaT 
Cytotoxicity analyses were performed in 96-well plates (Costar, 
Fisher Scientific) using alamarBlue® (Invitrogen) for cell 
viability detection using a modified protocol as described 
previously. HepG2 or HaCaT cells were subcultured at 37 °C, 
5% CO2 in DMEM high glucose supplemented with heat-
inactivated foetal bovine sera (FBS, 10%; Biosera Ltd) and 
penicillin/streptomycin (P/S, 1%). Cells were counted using a 
Neubauer Improved Haemocytometer. HepG2 cells were 
seeded 1 day prior to treatment in 96 well plates at a 
concentration of 2x10
5
 cells/mL in 100 µL of medium (2x10
4
 
cells/well). Then cells were pre-incubated with the compounds 
in triplicate in a dilution series in triplicate from 2 – 100 µM (5 
mM stock solutions in DMSO diluted from 100 µM to 3 µM; 
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untreated cells with DMSO as a negative control) in 50 µl of 
the media for 1 hour. Afterwards, 40 µL were removed from 
each well before the addition of 90 µL of the media, followed 
by incubation for 24 hours at 37 °C, 5% CO2. Then, 10 µL of 
alamarBlue® (Invitrogen) was added to each well before a 2 
hour incubation prior to assessing cell viability using a 
fluorescent plate reader (Biotek; Ex 560 nm / Em 600 nm). All 
data were measured in triplicate on a minimum of two 
occasions to ensure a robust data set was collected . The ED50 
values were calculated from the dose response results 
achieved from the serial dilutions. 
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The cytoxicity profiling of a series of linear peptoids 
against mammalian cell lines has been carried out 
and correlated against both antibacterial properties 
and hydrophobicity.  
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